Hepatocellular carcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:88673OMIM:114550C22.0
Who is this for?
Show terms as
2FDA treatments36Specialists8Treatment centers3Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

HCCHepatocellular carcinomaLiver cancer
Orphanet ↗OMIM ↗NORD ↗

Treatments

2 available

CABOMETYX

cabozantinib· Exelixis, Inc.

CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

View Details →FDA Label ↗

CYRAMZA

ramucirumab· Eli Lilly and Company

as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib

View Details →FDA Label ↗Patient Assistance ↗

Clinical Trials

View all trials with filters →

No actively recruiting trials found for Hepatocellular carcinoma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Hepatocellular carcinoma community →

Specialists

Showing 25 of 36View all specialists →
WM
Wei-Ting Chen, MD
HOUSTON, TX
Specialist
PI on 1 active trial
JM
Jeong Min Lee, MD
Specialist
PI on 6 active trials
BM
Binu V John, MD MPH
RICHMOND, VA
Specialist
PI on 1 active trial
AM
Anna S Lok, MD
ANN ARBOR, MI
Specialist
PI on 1 active trial1 Hepatocellular carcinoma publication
SD
Salih, Prof. Dr.
Specialist
PI on 1 active trial
MP
Mi-Sook Kim, MD, PhD
Specialist
PI on 2 active trials
EL
Edward Lin
Specialist
PI on 1 active trial22 Hepatocellular carcinoma publications
WM
Wei Wei, Ph.D, M,D
Specialist
PI on 1 active trial
CW
congren Wang
Specialist
PI on 1 active trial
YW
Yongzhong Wang
Specialist
PI on 1 active trial2326 Hepatocellular carcinoma publications
JC
Jiafei Chen
Specialist
PI on 1 active trial
JC
Jianbo Chen
Specialist
PI on 1 active trial
FY
Feng Ye
BURLINGTON, MA
Specialist
PI on 1 active trial
JY
Jieer Ying
Specialist
PI on 1 active trial11 Hepatocellular carcinoma publications
FL
Feng Lin
Specialist
PI on 1 active trial
QC
Qinghe Cai
Specialist
PI on 1 active trial
KP
Kai-Wen Huang, MD, MS, PhD
Specialist
PI on 1 active trial
KM
Kyung Suk Suh, MD
LOS ANGELES, CA
Specialist
PI on 1 active trial
KM
Kyle Cuneo, MD
ALPENA, MI
Specialist
PI on 1 active trial
MM
Michael Bitzer, MD
GRAYSLAKE, IL
Specialist
PI on 1 active trial
AM
Andrew Zhu, MD
Specialist
PI on 1 active trial
PM
Perre NAHON, MD-PhD
Specialist
PI on 1 active trial
OM
Osama M Elsanousi, MD
Specialist
PI on 1 active trial
MM
Murtada M Mohamed, MD
Specialist
PI on 1 active trial
NM
Ning Li, M.D.
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

3 resources
CYRAMZA(ramucirumab)— Eli Lilly and Company

TECENTRIQ

Genentech, Inc.

TECENTRIQ Patient Support (Genentech Access Solutions)

Patient Assistance
Manufacturer Program
Accepting applications

Avastin

Genentech, Inc.

Avastin Patient Support (Genentech Access Solutions)

Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Hepatocellular carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hepatocellular carcinomaForum →

No community posts yet. Be the first to share your experience with Hepatocellular carcinoma.

Start the conversation →

Latest news about Hepatocellular carcinoma

1 articles
Clinical trialUNITERAREApr 3, 2026
New Recruiting Trial: Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Researchers are testing a new combination of three drugs (RBS2418, tremelimumab, and durvalumab) to treat advanced hepatocellular carcinoma, a type of liver can…
See all news about Hepatocellular carcinoma →

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hepatocellular carcinoma

Which specialists treat Hepatocellular carcinoma?

25 specialists and care centers treating Hepatocellular carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Hepatocellular carcinoma?

3 patient support programs are currently tracked on UniteRare for Hepatocellular carcinoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.